Credit Suisse Ag Gemini Therapeutics, Inc. Transaction History

Credit Suisse Ag

  • $101 Billion
  • Q1 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022
BUY
$1.22 - $1.73 $14 - $20
12 New
12 $0

Others Institutions Holding GMTX

# of Institutions
1
Shares Held
2.44M
Call Options Held
0
Put Options Held
0
View Full List

About Gemini Therapeutics, Inc.

GMTX Quotes by TradingView
  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Credit Suisse Ag Portfolio

Follow Credit Suisse Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email